Post by
venture009 on May 26, 2023 8:34pm
Release
My take on yesterdays pre ASCO release is that it was good but not out of the park, which most, I believe, were expecting after Coffey's hype during his year end phone call. I was surprised with the high number of patients removed from the trial because of toxity. This almost seems similar to what happened during the H&N. Can't imagine they would make the same mistake twice infleuncing the outcome of the trial. Then again after 20 + years nothing coming from ONCY should be a surprise.
Since the main success was with Pfizers paxlitaxel and Pfizerer hasn't shown any interest. So now where do they go to get a partner or buyout. Perhaps the market is askig the same question.
Comment by
YegJeeber on May 26, 2023 11:58pm
Blah blah blah. This was data as of last October. The "real" data that Matt and company are excited about is live to this month, and has been reserved for the oral presentation at ASCO. But nice try in attempting to create FUD.